MariMed To Expand Brand Distribution To New York
Rhea-AI Summary
MariMed (CSE: MRMD / OTCQX: MRMD) announced a licensing agreement with Farm 2 Hand to introduce MariMed’s top-selling edibles across New York State.
Farm 2 Hand will manufacture and distribute Betty’s Eddies™, Bubby’s Baked™, and InHouse™ gummies from a new kitchen that MariMed will design and equip at Farm 2 Hand’s Bronx facility. Terms were not disclosed. MariMed expects products to reach New York’s 500+ dispensaries in 2026, pending the kitchen build-out and regulatory approval. The company cited New York’s $6 billion total addressable market as a strategic expansion opportunity to drive wholesale revenue and brand awareness.
Positive
- Expected distribution to 500+ New York dispensaries in 2026
- MariMed will design and equip Bronx kitchen for local production
- Licensing covers three named edibles brands: Betty’s Eddies, Bubby’s Baked, InHouse
Negative
- Agreement terms were not disclosed
- Product availability conditional on regulatory approval
- Launch timing depends on kitchen build-out at Bronx facility
- No financial guidance or revenue impact figures were provided
News Market Reaction – MRMD
On the day this news was published, MRMD gained 1.13%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NORWOOD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed,” “the Company”) (CSE: MRMD) (OTCQX: MRMD), a leading cannabis consumer packaged goods company and retailer, today announced a licensing agreement with Farm 2 Hand, LLC (“Farm 2 Hand”), a New York State cannabis license holder, that will introduce the Company’s top-selling portfolio of products throughout New York State. Terms of the agreement were not disclosed.
Farm 2 Hand intends to manufacture and distribute a variety of MariMed’s edibles products as permitted under New York regulations. Those are initially expected to include Betty’s Eddies™ fruit chews; Bubby’s Baked™ baked goods; and InHouse™ gummies. The products will be produced in a new kitchen that MariMed will design and equip for Farm 2 Hand at Farm 2 Hand’s Bronx production facility.
“Expanding the availability of our brands to the Empire State and its
The Company expects its products will be available to New York’s 500+ dispensaries in 2026, following the build-out of the kitchen and regulatory approval.
ABOUT MARIMED
MariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including Betty's Eddies™, Bubby’s Baked™, Vibations™, InHouse™, and Nature’s Heritage™, sets us apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry. For additional information, visit www.marimedinc.com.
IMPORTANT CAUTION REGARDING FORWARD-LOOKING STATEMENTS:
The information in this release contains “forward-looking” statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, which are subject to several risks and uncertainties. All statements other than statements of historical facts contained in this release, including without limitation statements regarding projected financial results for 2025, including anticipated openings of dispensaries and facilities, timing of regulatory approvals, plans and objectives of management for future operations, are forward-looking statements. Without limiting the foregoing, the words “anticipates”, “believes”, “estimates”, “expects”, “expectations”, “intends”, “may”, “plans”, and other similar language, whether in the negative or affirmative, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Forward-looking statements are based on our current beliefs and assumptions regarding our business, timing of regulatory approvals, the ability to obtain new licenses, permits, business prospects and strategic growth plan, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated in these forward-looking statements due to various risks, uncertainties, and other important factors, including, among others, reductions in customer spending, our ability to recruit and retain key personnel, and disruptions from the integration efforts of acquired companies.
These factors are not intended to be an all-encompassing list of risks and uncertainties that may affect our business and results of operations. These statements are not a guarantee of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company’s services and products, changes in the law and its enforcement, and changes in the economic environment. Additional information regarding these and other factors can be found in our reports filed with the U.S. Securities and Exchange Commission. In providing these forward-looking statements, the Company expressly disclaims any obligation to update these statements publicly or otherwise, whether as a result of new information, future events or otherwise, except as required by law.
All trademarks and service marks are the property of their respective owners.
MariMed Company Contact:
Howard Schacter, Chief Communications Officer
Email: hschacter@marimedinc.com
Phone: (781) 277-0007
FAQ
What did MariMed (MRMD) announce about New York distribution on October 23, 2025?
Which MariMed brands will be produced and sold in New York under the MRMD deal?
When does MariMed expect MRMD products to be available in New York dispensaries?
How many New York dispensaries could carry MariMed (MRMD) products?
Will MariMed manufacture products in New York under the MRMD agreement?
Did MariMed disclose financial terms or expected revenue from the New York licensing deal?
